Aurinia Pharmaceuticals has appointed Stepen Zaruby as president and CEO.
His career includes a 20-year stint at German company Bayer, including spells managing its domestic and international anti-infectives, quinolone and hospital/surgical business franchises.
Mmost recently he served as president at ZymoGenetics until its acquisition by Bristol-Myers Squibb in 2010. Since then he has worked as an independent consultant in life sciences.
Commenting on his latest appointment, Zaruby said he was looking forward to the future for kidney-focused Aurinia as it looks to launch its first drug.
“Aurinia is well positioned to bring voclosporin forward as an important new treatment for lupus nephritis,” he said.
Aurinia’s chair Dr Richard Glickman said: “Stephen is a seasoned leader with a strong track record of delivering strategic direction and operational excellence to both established and emerging life sciences companies.
“He is exceptionally qualified to help us build our voclosporin franchise and sharpen our execution.”